Corporate Presentation

November 2023

PeptiDream Inc.

(TSE : 4587)

PeptiDream

PeptiDream - Investment Highlights

Global Leader in the Discovery and Development of Macrocyclic Peptide Therapeutics

Industry Leading Peptide Discovery Platform

PeptiDream's proprietary Peptide Discovery Platform System (PDPS) technology

- Unparalleled peptide library generation (trillions) and hit finding platform
- Unrivaled # of building blocks
- Continuous evolution of the technology, translating learnings from advancing programs back into the platform improvements
- World-class chemistry, biology, bioinformatics, structural biology, modeling, profiling and ADME teams to turn hit peptide candidates into development candidates

Strong IP portfolio

Foundational in Leading and Expanding the Field

PeptiDream at the center of a large and diverse network of discovery and development partnerships

- Collaborations with large, mid, and small sized pharma companies all over the world creating the ecosystem
- Licensing of the PDPS discovery platform to global and Japan pharma partners solidifies the network around a common platform.
- Further grow the network and modality through strategic partnerships
- Develop products in house and license to network partners

PeptiDream

Diverse Big Pharma-Sized Pipeline

PeptiDream has a large diverse pipeline of programs spanning peptide modality, disease areas and development partners

- Over 120+ discovery and development programs
- Spans variety of peptide modalities, from peptide therapeutics to peptide-drug conjugates (PDCs) to multi-functional peptide conjugates (MPCs)
- Across broad range of therapeutic areas and discovery and development partners

Markets 24 radiodiagnostic and 8 radiotherapeutic products in Japan through PDRadiopharma

Business Model Driving Profitability and Growth

PeptiDream's unique multifaceted business model has allowed company to be profitable since 2011

- Year over year growth in revenue and profits from three complementary and synergistic business strategies
- Grow the business and the pipeline through partnerships and cash flow, not through capital raises
- Phenomenal growth potential as the pipeline matures

Japan radiopharmaceutical and radiodiagnostic business provides stable, positive cash flow

PeptiDream – Historical Snapshot

From University Startup to Growing Japan-Based Drug Discovery Powerhouse



PDRadiopharma Chiba Plant

PeptiDream headquarters (Kawasaki)

PeptiDream Founded
(Spinout from the University of Tokyo)

2006
Revenue/ Total employees

Listed on the TSE Mothers
(Ticker: 4587)

2013
JPY 0.6B / 32 employees

Changed to the first section of the TSE

2015
JPY 2.4B / 50 employees

Relocated corporate headquarters to Kawasaki

2017
JPY 4.8B/ 68 employees

Acquired PDRadiopharma Inc.
(Radiopharmaceutical business)
Changed to the Prime Market of the TSE

2022
JPY 26.8 B/ 680 employees

Selected as a constituent of The JPX Prime 150 Index

2023
JPY 30.0 B[1)]/ 704 employees[2)]

Note: Financial numbers prior to FY2021 are based on JGAAP, IFRS is applied after FY2022.
1) Consolidated revenue forecast for FY2023 2) PeptiDream Inc.: 208 employees, PDRadiopharma Inc.: 496 employees (as of June 2023)

PeptiDream's Equity Holdings

Key progress on programs with the partners





Radiopharmaceutical Development, Manufacturing and Sales (2022-)

- Indication expansion of AMYViD approved for the use of MCI
- In-licensing discussions to accelerate short-term pipeline growth



<5%

Computational Drug Discovery (2017-)

- Partnering discussions in progress for KIT inhibitor program

2%

Strategic Partner in Radiopharmaceuticals (2020-)

- Announced the 2nd development candidate from PeptiDream collaboration
- IND-enabling studies and imaging studies in humans on-going, with the plan to file INDs in H1 2024

<15%

Peptide CDMO Business (2017-)

- Expanding the peptide and oligonucleotide API manufacturing business
- Progress in development of new platform technologies

39.5%

Growth Factor Business (2020-)

- 7 products currently in the market
- Targeting market opportunities in lab-grown meat in addition to regenerative medicine and cell therapy
- Partnering discussions for therapeutic use

39.4%

100%

COVID-19 Therapeutics (2020-)

- Confirmed favorable safety profile in humans (clinical research in Japan)
- Anticipate US phase 1 trial to start in Q1 2024, with financial support from AMED

Note: (Year) represents the year that PeptiDream invested in the company.

Macrocyclic Peptides as an Expanding Drug Class

Several Approved Macrocyclic Peptide Drugs With Over $1B in Annual Sales

PeptiDream

Long History of Macrocyclic Peptides As Drugs



Blockbuster Macrocyclic Peptides

Drug name	Indication	Peak Sales ($M)
Restasis (cyclosporine)	Chronic dry eye	1,488
Somatuline (lanreotide)	Acromegaly; Neuroendocrine tumors	1,424
Sandostatin (octreotide)	Acromegaly; Symptoms of Carcinoid tumors and VIPomas	1,413
Sandimmune/Neoral (cyclosporine)	Transplant rejection	1,338
Cubicin (daptomycin)	complicated skin and skin structure infections (cSSSI)	1,187

Macrocyclic Peptides Have Positive Features of Both Small & Large Molecules



Small molecules

- Good at recognizing binding pockets but not PPIs or shallow surfaces
- Orally bioavailable
- Membrane permeable
- Near limitless targets
- However difficult and time consuming to find

Macrocyclic peptides



- High affinity and specificity
- Good at inhibiting PPIs
- Good at recognizing shallow interacting surfaces and binding pockets
- Oral bioavailability possible
- Near limitless targets
- Relative ease and speed in finding a suitable hit

Large molecules



- High affinity and specificity
- Good at inhibiting PPIs
- Good at recognizing shallow interacting surfaces of proteins
- Not oral – limited targets
- Relative ease and speed in finding a suitable hit

Most approved macrocyclic drugs arose from natural products, limiting discovery!

Note: 1) Approved by CDER (Center for Drug Evaluation and Research) as new molecular entities.
Source: FDA, Chemistry & Engineering News, Company websites.

PDPS is a Powerful Peptide Discovery Platform

Unparalleled Macrocyclic Peptide Library Generation and Hit Finding Technology

PeptiDream

Amino Acid (AA) Building Blocks



PeptiDream's 3000+ AAs:

- Canonical AAs
- Non-canonical AAs
  - L-AAs w/ novel side chains
  - N-alkyl AAs
  - *D*-AAs
  - β-AAs
  - Peptoid AAs

  etc.

Randomized DNA library



10 positions with 20 building blocks

20^{10} = 10,240,000,000,000 different peptides in a library

Trillions of peptides in each library

- ✓ Robust, cell-free synthesis derived by nature's way of making peptides
- ✓ Each peptide "barcoded" via its mRNA/cDNA tag







Amplify recovered sequences and repeat



Amplify candidate peptides over iterative rounds of selection

Automated PDPS Workstation



Target protein

Peptide binder

High rate of hit finding success

- ✓ Discover high affinity and highly selective macrocyclic peptide binders to almost any target quickly and efficiently
- ✓ Yields unique hit candidates unlike any other technology
- ✓ Technology can be used to optimize and fine-tune the drug-like properties

Continuously evolving platform

- ✓ Continuous expansion of AA building blocks that libraries can be made with and optimized from (grew from 200 to >3,000)
- ✓ Automation of the platform (high throughput)
- ✓ Growing in-silico methods, computer simulation and modeling to predict optimal features
- ✓ Protected by a broad patent portfolio

The Expanding Applications of Macrocyclic Peptides

Turning PDPS Identified Seeds Into a Growing Array of Peptide Therapeutics

PDPS Identified Macrocyclic Peptide Seeds





Key Advantages

- **Affinity and selectivity** comparable to antibodies
- Unique epitopes and **MOAs**
- Differentiating PK & ADME characteristics
- **Oral administration** & other routes possible
- Enable small molecule discovery

- **Peptide ideal at targeting and payload delivery**
- More amenable to a greater array of payloads compared to other modalities.
- Simple robust conjugation chemistry
- Tunable PK/ Differentiating route of elimination

- **RI-PDC: Ideal fit** with radioisotope payloads
- **Oligo-PDC:** Enable **delivery of oligonucleotide/siRNA** drugs to specific tissues/cells
- **Cytotoxic-PDC:** unique beneficial attributes

- Extremely powerful and modular
- Design and generate **multi-functional peptide drugs** by conjugating/linking several peptides with different MOAs together
- Various configurations, such as bifunctional, trifunctional, and more

Expansion of R&D Capabilities

Unlocking Greater Value and Increasing Control

PeptiDream's role in collaborations has increased over time

R&D Capabilities (2010)



R&D Capabilities (2023)



Increasing research capabilities allows for:

- Greater role in partnerships
- More control over program progress
- Larger deal financials
- Ability to take internal programs further before partnering/ out-licensing



Unique Multifaceted Business Model

Business Model Spread Across 4 Strategies

PeptiDream

PeptiDream

Drug Discovery and Development Business Segment

1. **Collaboration Drug Discovery and Development**
2. **PDPS Technology Licensing**
3. **Strategic Alliance/ In-House Program**

Radiopharmaceuticals Business Segment

100% PDRadiopharma

4. **R&D, Manufacturing and Sales of Radiopharmaceuticals/Diagnostics**

Revenue Source		
Short-term	**Mid-term**	**Long-term**
Upfront Research funding Preclinical milestones	Development milestones	Royalties
Licensing and maintenance fees	Development milestones	Royalties
	Out-licensing fee, development milestones	Royalties
Product Sales (Existing products)	Product Sales (In-licensed products)	Product Sales (PeptiDream products)

1 Collaboration Drug Discovery and Development

Combining PeptiDream's Expertise With Big Pharma's Drug Development Know-How and Capabilities

- **Lead & Expand:** Leadership position in the space – drive expansion of macrocyclic peptide ecosystem
- **More Programs:** Allows PeptiDream to work on a larger number of programs with less staff/resources than otherwise possible
- **Build Expertise:** Continuously build in-house expertise by working with and learning from big pharma
- **Diversify Risk:** Diversify business risk with a broad portfolio of programs and partners (success not tied to any one program or partner)

5-Year Snapshot



Note: Merck & Co., Inc., Rahway, NJ, USA.

2 PDPS Technology Transfer/Licensing

Transfer and Establish Operation of PDPS Technology Within Partner Companies

- **Platform Validation:** Non-exclusively licensed PDPS technology to 11 companies
- **Establish as Standard:** Make PDPS technology the global standard to discover macrocyclic peptides
- **Grow People:** Partners expand staff, resources, capabilities around PDPS and peptide discovery and development
- **Licensing Revenue:** PeptiDream receives licensing revenue along with downstream milestones/royalties on any products
- **Carveout PDCs:** PDPS technology licenses included PDC carveout, partners must work with PeptiDream to do PDCs



Note: Merck & Co., Inc., Rahway, NJ, USA.

3 In-House/Strategic Discovery and Development

Growing and Accelerating In-house Discovered Programs Through Strategic Partnerships

- **Access expertise/technology:** Access to expertise and/or technology/know-how PeptiDream does not possess
- **Increased Speed/Control:** Streamlined focus and decision making, defined roles, greater control = program acceleration
- **Greater Upside:** Faster and greater monetization of programs at lower cost/risk

In-House Programs

Develop internally and out-license to third party for clinical development

Jan 2018

PeptiDream

- Started internal program to develop GhR antagonists

Dec 2020

AMOLYT PHARMA

- Formed strategic partnership with licensing option

Sep 2021

- Amolyt exercised license option

June 2023

- Amolyt Initiated Phase1 Clinical Trial

Strategic Partnership

Joint - Development and out-license to third party for clinical development

Feb 2016

PeptiDream JCR Pharmaceuticals

- Started research collaboration

May 2019

- Successfully identified TfR binding peptides that could deliver to muscle and CNS

Dec 2020

Takeda

- Exclusive research and license deal to peptide-oligo PDCs for neuromuscular diseases

Jul 2021

Takeda

- Extended deal to certain CNS targets

Preclinical Collaboration

Joint – Development and partner takes over clinical development

Jul 2017

- Started research collaboration with Biohaven

Jun 2019

- Identified CD38-ARM™ as clinical candidate

Feb 2020

- IND authorization obtained for CD38-ARM™

Sep 2020

- Orphan Drug Designation by FDA to CD38-ARM™

Oct 2021

- Phase1a/1b started for CD38-ARM™

4 Global Radiopharmaceutical Market

Experiencing Significant Growth From Targeted Radiotherapeutics/Diagnostics

- **Targeted radiotherapy:** Lutathera and Pluvicto demonstrating high efficacy – driving further investment/products in the space

Market Growth

Worldwide



Japan

Larger growth in RI therapeutics is expected in Japan market



Major Players

- Novartis/AAA
- Bayer
- Lantheus
- Curium
- ITM
- Eli Lilly/Avid
- Point Biopharma
- RayzeBio
- PDRadiopharma
- Nihon Mediphysics

Clinical Pipeline and Marketed Radiotherapeutics[2)]

Company	SSTR	PSMA	FAP	HER2	NTSR1	GRPR	CAIX	CD45	B7H3	CD33	CD66	LAT1	EGFR/cMET	IGF-1R	Integrin αvβ3/5	hK2	PARP	CAXII
Novartis	■	■	□			□									□			
Telix Pharmaceuticals		□					□				□	□						
Point Biopharma	□	□	□															
Fusion Pharma		□			□								□	□				
Clarity Pharmaceuticals	□	□				□												
ITM	□	▒																□
Full Life/ Focus X	▒	□			▒													
Actinium Pharmaceuticals								□		□								
Ariceum Therapeutics	□																□	
Bayer		□		□														
Lantheus	□	□																
Precirix			▒	□														
Radiomedix	□	□																
Andarix	□																	
CellBion		□																
Curium		□																
Debiopharm							□											
FutureChem		□																
Johnson and Johnson																□		
RayzeBio	□																	
Y-mAbs									□									

■ = Marketed □ = Clinical stage ▒ = Preclinical stage

Note: 1) Estimate from the data of JRIA, Exchange rate JPY/USD=140; 2) Partnered programs may be counted twice (e.g., Point Biopharma and Lantheus).
Source: 1) JRIA, Global information, Analysis of BofA 2) Company websites as of end of July 2023

4 PD/PDR Ideally Positioned to be a Major Player

Leveraging PD's Radiotherapeutic Discovery Role With PDR's Unique Japan Market Presence

Key Features of the Radiopharmaceutical Market in Japan

- Only 2 licensed radiopharmaceutical companies in Japan due to highly regulated market
- High barrier to Japan market entry, strict regulations and supply chain requirements to handle radiopharmaceuticals
- Partnering with a local Japanese company is essential for global pharma companies to commercialize their radiopharmaceutical products in Japan

PeptiDream

- Already playing a leading global role in the discovery and development of target radiotherapies (peptide-RI conjugates) through partnerships with Novartis, RayzeBio and Bayer
- Growing pre-clinical pipeline of peptide-RI conjugates
- Strong global reputation and connections with big pharma and the other major radiopharmacuetical players

⊕

PDRadiopharma

- Founded in 1968: experts with deep experience in radiopharmaceuticals
- Long relationships with regulators, KOLs, radiologists/hospitals
- Vertically integrated infrastructure with R&D, manufacturing and commercialization capabilities in Japan
- 8 therapeutic and 24 diagnostic products on the market
- Network of global radioisotope suppliers and vendors

Combining with PDRadiopharma enables PeptiDream to both accelerate and maximize the value of the peptide-RI products it is discovering and developing

PD/PDR Radiopharmaceutical Product Offerings

3 Strategies to Grow PD/PDR Product Portfolio and Revenue



PeptiDream Pipeline Snapshot

Consistent Year-Over-Year Advancement of Programs Through Preclinical Into Clinical Development

Number of programs per stage



Recent Highlights:

MERCK	Undisclosed	Undisclosed	• Initiated Phase 1 in July 2023 • Derived from PDPS technology licensing
AMOLYT PHARMA	AZP-3813	Acromegaly, Others	• Licensed to Amolyt • Initiated Phase 1 Clinical Trial in June 2023 • Presented preclinical results at ENDO/ECE
RayzeBio	RI-PDC	Oncology	• Partnered with RayzeBio • Nominated two development candidates arising from the strategic partnership, including GPC3 program against HCC (March 2023) • As for GPC3 program, IND-enabling study and human imaging testing is ongoing , with the plan to file INDs in H1 2024
PeptiAID	S2-protein antagonist	COVID-19	• Safety and dose-dependent pharmacokinetics profile were observed in Clinical research conducted in Japan (jRCTs031210601); • Aims the start of Ph1 study in 2024 1H
Bristol Myers Squibb	PD-L1 inhibitor	Oncology	• Initiated Phase 1 in April 2022 (QSC203717) • Blockbuster potential
Biohaven	CD38-ARM™	Multiple myeloma	• Received FDA orphan drug designation in 2020 • Initiated Phase 1a/1b in October 2021 • Reported good progress

Note: Numbers do not include programs at PDRadiopharma. The number of programs after Phase1 includes programs implemented by partners of PDPS technology license

PeptiDream's Clinical Stage Pipeline

Program	Indication	Partner	Pre-clinical / Clinical (Ph1 / Ph2 / Ph3)	Status
PD-L1 Therapeutic Peptide	Oncology	Bristol Myers Squibb™		Phase 1 started Apr. 2022 (ISRCTN17572332) • Assessment the safety and tolerability of PD-L1 inhibitor in healthy subjects
PD-L1 BMS-986229 RI-PDC (PET diagnostic)	Oncology	Bristol Myers Squibb™		Phase 1 started Nov. 2019 (NCT04161781) • ^{18}F-labeled PET tracer that specifically binds to cancer cells expressing PD-L1 • Evaluate PD-1/PD-L1 expression in patients
CD38 BHV-1100 + NK Cells Therapeutic MPC	Multiple Myeloma	Biohaven		Phase 1a/1b started Oct. 2021 (NCT04634435) • Evaluate the safety, tolerability, and exploratory efficacy in multiple myeloma patients • Orphan Drug Designation
GhR AZP-3813 Therapeutic Peptide	Acromegaly/NET	AMOLYT PHARMA		Phase 1 started Jun. 2023 • Evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following single and multiple ascending doses in healthy subjects
Undisclosed Therapeutic Peptide	Undisclosed	MERCK		Phase 1 started Jul. 2023
S2-protein PA-001 Therapeutic Peptide	COVID-19	PeptiAID		Safety and clear dose-dependent pharmacokinetics profile were observed in Clinical research conducted in Japan (jRCTs031210601); • Aims the start of Ph1 study in 2024 1H

Note: As of August 2023, Merck & Co., Inc., Rahway, NJ, USA.

PeptiDream's Late-Stage Pre-Clinical Pipeline

Program	Indication	Partner	Pre-clinical	Clinical Ph1	Clinical Ph2	Clinical Ph3	Status
Glypican-3 RI-PDC	Liver Cancer	RayzeBio					Selected clinical candidate (Mar. 2023) Clinical Imaging/IND enabling, , with the plan to file INDs in H1 2024
Undisclosed RI-PDC	Oncology	RayzeBio					Selected clinical candidate (Dec. 2022) GLP-Tox to IND stage
KIT Therapeutic Small Molecule	Mast Cell-Driven Allergic Diseases	MODULUS					Selected Clinical Candidate (Aug. 2023) Partnering discussions
Myostatin Therapeutic Peptide	Obesity/SMA/DMD/ Muscle Disorders	In-house (Kawasaki Med. School)					Selecting clinical candidate Partnering discussions
Undisclosed RI-PDC	Oncology	NOVARTIS					Lead to GLP-Tox stage
TfR Oligo-PDC	Neuromuscular Disorders	Takeda					Lead to GLP-Tox stage
c-Met Therapeutic Peptide	Undisclosed	Genentech A Member of the Roche Group					Lead to GLP-Tox stage
Undisclosed Therapeutic Peptide	Undisclosed	AsahiKASEI					Lead to GLP-Tox stage
Undisclosed Therapeutic MPC	Undisclosed	Undisclosed	Santen				Lead to GLP-Tox stage
HA-protein PD-001 Therapeutic Peptide	Influenza	In-house					Considering partnering options in light of changing global market environment

Note: As of August 2023, above list not inclusive of all programs

PDRadiopharma Product Portfolio

8 Therapeutic and 24 Diagnostic Products on the Market

PeptiDream

- Promote use and indication expansion of existing approved products

	Product/Program Target	Radio-isotope	Indication	Partner	Preclinical	Clinical			Marketed
						Ph1	Ph2	Ph3	
Tx	Sodium Iodide Capsule	^{131}I	Hyperthyroidism/Primary and Metastatic Thyroid Cancer	In-house					
Tx	Raiatt MIBG	^{131}I	MIBG avid Pheochromocytoma/ Paraganglioma	In-house					
Tx	Zevalin® CD20	^{90}Y	Low-grade non-Hodgkin's B-cell Lymphoma/Mantle Cell Lymphoma	Mundipharma					
Dx	OctreoScan® SSTR	^{111}In	Somatostatin Receptor Scintigraphy	Curium					
Dx	Techne® MDP	^{99m}Tc	Bone Scintigraphy	In-house					
Dx	Neurolite®	^{99m}Tc	Cerebral Blood Flow	Lantheus Medical Imaging					
Dx	Cardiolite®	^{99m}Tc	Heart Disease/ Hyperparathyroidism	Lantheus Medical Imaging					
Dx	MyoMIBG®	^{123}I	Heart Disease/ Pheochromocytoma/ Neuroblastoma	In-house					
Dx	Tl201	^{201}Tl	Heart Disease	In-house					
Dx	Ultra-Techne Kow®	^{99m}Tc	Brain Diseases/Thyroid Disease/Salivary Gland Disease	In-house					
Dx	Amyvid® β-Amyloid	^{18}F	Visualization of beta amyloid plaques in the brain of patients with MCI or suspected to have dementia due to AD	Eli Lilly/ Avid Radiopharmaceuticals					
Dx	FDG	^{18}F	Malignant Tumor/ Heart Disease/ Intractable Partial Epilepsy/ Large-vessel Vasculitis	In-house					

Note: Tx: Therapeutics, Dx: Diagnostics; FDG = Fluorodeoxyglucose; AD: Alzheimer's disease; MCI: mild cognitive impairment. As of August 2023.

Clinical Pipeline of PDRadiopharma

- 4 clinical-stage programs currently in development
- Planning to further expand PDRadiopharma's pipeline and product portfolio in the future
  - In-license assets already approved or in late-stage development overseas / service agreements to develop/commercialize in Japan
  - Develop PeptiDream's in-house and partnered development programs in Japan

	Program/ Target	Radioisotope	Indication	Clinical			Marketed	Notes
				Ph1	Ph2	Ph3		
Dx	Tauvid® Tau	^{18}F	Alzheimer's disease	Co-development with Eli Lilly in Japan / US (Eli Lilly)				Approved by US FDA in 2020
Dx	F-1311 PSMA	^{99m}Tc	Prostate cancer	Japan (PDR) / US (Lantheus)				In-licensed from Lantheus Medical Imaging
Thx	FF-10158 Integrin αvβ3/5	^{68}Ga/ ^{177}Lu	Malignant glioma and others	US/ EU (NVS)				Out-licensed ex-Japan rights to Novartis PDR retains Japan rights
Thx	PPMX-T002 Cadherin3	-	Advanced and recurrent solid tumors	Japan (PPMX) / US (PPMX)				Co-owned with Perseus Proteomics (PPMX) PPMX leading out-licensing activities

Note: Dx: Diagnostics, Thx: Theranostics; As of July 2023.

PeptiDream Financial Performances and Near-term Catalysts

Year-Over-Year Revenue and Profit Growth

Financial performance

- Consistent revenue and profit growth
- Reinvesting profits to further grow the business and pipeline
- Acquisition of PDRadiopharma adds cash flow/revenue
- Goal of JPY100B in revenue by 2030



Market Capitalization[1)] (As of Oct. 31, 2023)	JPY 141.7 B

Future catalysts

- **Progress of On-going Clinical Programs**
  - Next-Generation PD-L1 Inhibitor (BMS): Ph1 clinical results
  - CD38-ARM (Biohaven): Ph1a/1b clinical results
  - AZP-3813 (Amolyt): Ph1 clinical results
  - New target (MSD): Ph1 clinical results
- **Initiation of New Clinical Programs**
  - GPC3 (RayzeBio): IND-enabling study, entry into clinical trials
  - RI-PDC Program (in-house): Selection of development candidate
  - Myostatin Inhibitor (in-house): Selection of development candidate/ out-licensing
  - Oligo-PDC Program (Takeda/ Alnylam) : Selection of development candidate
  - Other programs (undisclosed): Selection of development candidate
- **Other Catalysts**
  - New license/collaboration agreements
  - Milestone achievements on existing programs
  - Partnering for KIT selective inhibitor (Modulus)
  - Development of new radiopharmaceuticals in Japan, new partnering

Note: From FY2019, fiscal year end changed from changed from June 30 to December 31. The financial performance between 2019/7 and 2019/12 (6 months) are excluded from this figure.
1) Yahoo! Finance.

References

Leadership Team at PeptiDream

Representative Director, President, CEO

Patrick C. Reid, Ph.D.

- Co-founder of PeptiDream, after working as Associate Professor at University of Tokyo
- CSO, Head of R&D until 2017
- CEO at PeptiDream 2017 to current
- Ph.D. in Biochemistry from Dartmouth Medical School

Director, COO

Keiichi Masuya, Ph.D.

- Joined PeptiDream in Jul 2014, previously Head of PPI Drug Discovery at Novartis International AG
- Director of PDRadiopharma, Director at PeptiGrowth, Representative Director and President at PeptiAID
- Ph.D. in Chemistry from Tokyo Institute of Technology

Director, CFO

Kiyofumi Kaneshiro, Ph.D.

- Joined PeptiDream in Jan 2018, previously Partner and Managing Director at the Boston Consulting Group
- Director of PDRadiopharma, Director at PeptiAID
- Ph.D. in Oncology from University of Tokyo

Chief Medical Officer

Masato Murakami, M.D., Ph.D., MBA

- Joined PeptiDream in Jan 2022, previously Vice President of the Global Precision Medicine Department at Daiichi-Sankyo
- M.D. from Tokai University School of Medicine (trained pathologist)
- Ph.D. in Medicine from University of Tokyo

Head of Business Development

Yen Ting Chen, Ph.D.

- Joined PeptiDream in May 2022, previously Vice President at Locust Walk Japan
- Ph.D. in Chemistry from Brown University

Head of IR & Public Affairs

Yuko Okimoto, Ph.D.

- Joined PeptiDream in May 2020, previously Director at Global Investment Banking Division of Mizuho Securities
- Ph.D. in Chemistry from University of Tokyo

External Directors at PeptiDream

Independent External Director
(Auditing Committee Member)
Michio Sasaoka, Ph.D.

- Joined PeptiDream in May 2012, after working at Massachusetts Institute of Technology as Postdoctoral Research Associate, Otsuka Chemical Co., Ltd. as Director of Explorative Laboratory
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Independent External Director
(Auditing Committee Member)
Junko Utsunomiya (Attorney)

- Joined PeptiDream in Mar 2021, after working at Nagashima Ohno & Tsunematsu, Utsunomiya Shimizu & Haruki Management Legal Office as a founding partner
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Independent External Director
(Auditing Committee Member)
Toshio Nagae

- Joined PeptiDream in Sep 2015, after working at Shionogi & Co., Ltd., Sanofi K.K. as Executive Officer of Aventis Pharma, York Pharma K.K as President and Representative Director
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Independent External Director
(Auditing Committee Member)
Yukinori Hanafusa (Certified Public Accountant)

- Joined PeptiDream in Mar 2016, after working at Aoyama Audit Corporation, Accounting Works Co., Ltd. as Founding Representative Director, ARCLAND SERVICE HOLDINGS CO., LTD as Director
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Forward-Looking Statements

This presentation contains forward-looking statements. These forward-looking statements are current plans, forecasts, assumptions and strategies based on currently available information. There are various inherent risks as well as uncertainties involved. The actual results of business performance may differ from those forecasts due to various factors.

These factors include, but are not limited to: (1) risks of delays, interruptions or failures associated with drug discovery and development; (2) risks of unexpected program disruptions or terminations due to changes in client policies; (3) risks associated with manufacturing products and the procurement of raw materials; (4) the impact of reduced competitiveness due to the competitors and competing technologies; (5) declining product sales capabilities; (6) adverse rulings in infringements or significant litigation against our Group's intellectual property rights; (7) adverse changes in economic conditions and related laws and regulations; and (8) fluctuations in interest rates and currency exchange rates.

The information in this material with respect to drugs (including those under development) is not intended to provide advertising or medical advice.

This material is intended to provide information on our Group's business and is not intended to solicit investment in securities.

PeptiDream assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.